FINWIRES · TerminalLIVE
FINWIRES

Needham Initiates Immix Biopharma at Buy With $21 Price Target

By

Immix Biopharma (IMMX) has an average rating of buy and mean price target of $19.94, according to analysts polled by FactSet.

What else is happening in Research?